Home Search
cannabinoids - search results
If you're not happy with the results, please do another search
CB2R agonists in the clinics: A treasure chest for treating inflammatory diseases
Researchers give an update on clinical trials with CB2R agonists and their potential for the treatment of inflammatory diseases.
CBD benefits to help you take control of your health
Savage Cabbage Ltd discuss CBD benefits and how they specifically work to aid anxiety, stress, sleep problems and menopause symptoms.
Your CBD routine: What is the best time time to take CBD?
Savage Cabbage discusses the perfect CBD routine designed by you.
Why does cannabis give us the “munchies”? Tests on worms could give clues
Researchers looking to see if giving worms cannabinoids alters their existing food preferences find that worms get the “munchies” too.
Targeting the Cannabinoid Type-2 Receptor for Novel Anto-inflammatory Therapeutics
Type-2 cannabinoid receptor (CB2R) is a G-protein-coupled receptor (GPCR) and an essential element of the endocannabinoid system (ECS) [1].
Visualizing the anti-inflammatory cannabinoid Type-2 receptor
Medicinal chemists describe how small molecule probes allow for the detection of CB2R, and thereby enable the discovery of novel anti-inflammatory treatments.
What is the ‘entourage effect’ of cannabis and how can it relieve pain?
The ‘entourage effect’ of cannabis comes from the pain-relieving effects of the plant, but could we boost this pain-relieving efficacy of THC without the psychoactive side effects?
How clarity and standards can help the CBD Industry to thrive
Michael Sassano, CEO at SOMAÍ Pharmaceuticals, walks us through how clarity and standards can help the CBD Industry to thrive.
Challenges bringing CB₂R medicine to bedside
Drug hunters explain how to overcome pitfalls on the way to CB2R medicine and therapeutics.
Hemp & CBD – A legitimate industry framework
Here, Savage Cabbage Ltd argue for a legitimate Industry Framework when it comes to hemp & CBD
Evaluating a novel treatment for opioid use disorder based on dual-brain psychology and photobiomodulation
Dr. Fredric Schiffer, founder and CEO of MindLight, LLC, looks at treatments for opioid use disorder based on Dual-Brain Psychology and photobiomodulation. Dr. Schiffer is also a part-time assistant professor in psychiatry at Harvard Medical School.
What can the UK Government do for access to cannabis and CBD Reform
Pointing to advancements in public health, the UK government can improve access to cannabis by altering its CBD reform.
Is CB₂R a hidden treasure trove for treating inflammatory diseases?
Expert scientists working on endocannabinoid system (ECS) trials explain how CB₂R can be used to treat inflammatory diseases.
Will CBD replace opioids?
America is gripped by opioid addiction and a dangerous opioid epidemic - could CBD be a viable replacement?
Cannabis legalisation will cost big pharma billions
Cannabis legislation is threatening to reduce pharmaceutical stock value by billions of dollars as more people are predicted to opt for weed over opioids.
What can the UK government do for the legalisation of medical cannabis?
Medical cannabis remains difficult to attain in healthcare under the British government, but it holds great promise for both NHS patients and the economy.
Methamphetamine epidemic in rural America drives overdoses
Methamphetamine, commonly referred to as meth, is prevalent in much of rural America and is driving overdoses.
CBD effective for chronic and severe anxiety
Cannabidiol, more commonly known as CBD, may halve the severity of symptoms and impairment caused by chronic anxiety.
Vitamin B6 supplements help reduce anxiety and depression
Taking high-dose vitamin B6 tablets can reduce feelings of anxiety and depression, new research reveals.
The importance of personalised medicine & technology in the future of medical cannabis
Dr Stephen Barnhill M.D from Apollon Formularies Plc discusses the potential for technology to upgrade personalised medicine for cannabis treatments.